Nonoperative management of hyperparathyroidism: present and future

被引:10
作者
Weigel, RJ [1 ]
机构
[1] Stanford Univ, Sch Med, Stanford, CA 94305 USA
关键词
D O I
10.1097/00001622-200101000-00007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Parathyroidectomy provides effective treatment for primary and secondary hyperparathyroidism with a predictable response of symptoms related to hypercalcemia and elevated parathyroid hormone. Calcium and vitamin D supplementation has reduced the need for parathyroidectomy in dialysis patients with secondary hyperparathyroidism. However, surgery continues to be the only effective treatment of primary hyperparathyroidism, Potential nonoperative treatments for hyperparathyroidism have included the use of estrogen replacement, bisphosphonates, and a new class of drugs known as calcimimetics, Hormone replacement therapy with estrogen has been reported to improve cortical bone density in postmenopausal women with asymptomatic or mildly symptomatic primary hyperparathyroidism. Calcimimetic agents are a new class of drugs that increase the sensitivity of the calcium receptor to ionized calcium. Initial studies have shown that calcimimetics can acutely lower parathyroid hormone levels in patients with primary and secondary hyperparathyroidism. These drugs are currently being evaluated in phase tl clinical trials. Ultimately, these medical modalities will need to be compared to parathyroidectomy in randomized controlled clinical trials. Curr Opin Oncol 2001, 13:33-38 (C) 2001 Lippincott Williams & Wilkins, Inc.
引用
收藏
页码:33 / 38
页数:6
相关论文
共 55 条
[1]   DURATION OF THE EFFECTS OF INTRAVENOUS ALENDRONATE IN POSTMENOPAUSAL WOMEN AND IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM AND PAGETS-DISEASE OF BONE [J].
ADAMI, S ;
ZAMBERLAN, N ;
MIAN, M ;
DORIZZI, R ;
ROSSINI, M ;
BRAGA, B ;
GATTI, D ;
BERTOLDO, F ;
LOCASCIO, V .
BONE AND MINERAL, 1994, 25 (02) :75-82
[2]   A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure -: Rapid communication [J].
Antonsen, JE ;
Sherrard, DJ ;
Andress, DL .
KIDNEY INTERNATIONAL, 1998, 53 (01) :223-227
[3]   Calcitriol pulse therapy is not more effective than daily calcitriol therapy in controlling secondary hyperparathyroidism in children with chronic renal failure [J].
Ardissino, G ;
Schmitt, CP ;
Testa, S ;
Claris-Appiani, A ;
Mehls, O .
PEDIATRIC NEPHROLOGY, 2000, 14 (07) :664-+
[4]   Markedly reduced activity of mutant calcium-sensing receptor with an inserted Alu element from a kindred with familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism [J].
Bai, M ;
Janicic, N ;
Trivedi, S ;
Quinn, SJ ;
Cole, DEC ;
Brown, EM ;
Hendy, GN .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (08) :1917-1925
[5]   The evolution of parathyroidectomy failures [J].
Boggs, JE ;
Irvin, GL ;
Carneiro, DM ;
Molinari, AS .
SURGERY, 1999, 126 (06) :998-1002
[6]   CLONING AND CHARACTERIZATION OF AN EXTRACELLULAR CA2+-SENSING RECEPTOR FROM BOVINE PARATHYROID [J].
BROWN, EM ;
GAMBA, G ;
RICCARDI, D ;
LOMBARDI, M ;
BUTTERS, R ;
KIFOR, O ;
SUN, A ;
HEDIGER, MA ;
LYTTON, J ;
HEBERT, SC .
NATURE, 1993, 366 (6455) :575-580
[7]   Mutations in the calcium-sensing receptor and their clinical implications [J].
Brown, EM .
HORMONE RESEARCH, 1997, 48 (05) :199-208
[8]   The extracellular calcium-sensing receptor: Its role in health and disease [J].
Brown, EM ;
Pollak, M ;
Hebert, SC .
ANNUAL REVIEW OF MEDICINE, 1998, 49 :15-29
[9]  
CHATTOPADHYAY N, 2000, UBCB, V32, P789
[10]   Outpatient minimally invasive parathyroidectomy: A combination of sestamibi-SPECT localization, cervical block anesthesia, and intraoperative parathyroid hormone assay [J].
Chen, H ;
Sokoll, LJ ;
Udelsman, R .
SURGERY, 1999, 126 (06) :1016-1021